Dopamine Hydrochloride Injection

The effect of stimulating adrenaline receptors in the sympathetic nervous system and dopamine receptors located in the kidneys, mesentery, coronary arteries, and cerebral arteries is dose-dependent. (1) At low doses (0.5-2 mu;g/kg per minute based on body weight), it mainly acts on dopamine receptors, dilating renal and mesenteric blood vessels, increasing renal blood flow and glomerular filtration rate, and increasing urine volume and sodium excretion; (2) At small to medium doses (2-10 mu;g/kg per minute based on body weight), it can directly stimulate beta;1 receptors and indirectly promote the release of norepinephrine from storage sites, exerting a positive stress effect on the myocardium, increasing myocardial contractility and stroke volume, and ultimately increasing cardiac output, systolic blood pressure, and possibly pulse pressure, with no change or slight increase in diastolic blood pressure, and usually no change in total peripheral resistance, while coronary blood flow and oxygen consumption improve; (3) At high doses (greater than 10 mu;g/kg per minute based on body weight), it stimulates alpha;1 receptors, leading to increased peripheral vascular resistance, renal vasoconstriction, and reduced renal blood flow and urine volume. Due to the increase in cardiac output and peripheral vascular resistance, both systolic and diastolic blood pressure increase. ① It has a much stronger effect on stimulating cardiac beta-1 receptors and increasing myocardial contractility; ② It can prevent the malignant development of shock caused by ischemia of these organs by increasing the blood flow to the kidneys and mesentery. Under the same condition of increasing myocardial contractility, the effects of causing arrhythmias and increasing myocardial oxygen consumption are weaker. In short, dopamine is particularly suitable for shock patients with weakened myocardial contractility, reduced urine output, and sufficient blood volume.

Dopamine hydrochloride. Its chemical name is: 4-(2-aminoethyl)-1,2-benzenediol hydrochloride. Molecular formula: C8H11NO2?HCl Molecular weight: 189.64

This product is a colorless clear liquid.

It is suitable for shock syndrome caused by myocardial infarction, trauma, endotoxin sepsis, heart surgery, renal failure, congestive heart failure, etc.; shock cannot be corrected after blood volume supplementation, especially shock with oliguria and normal or low peripheral vascular resistance. Because this product can increase cardiac output, it is also used for heart failure that is ineffective with digitalis and diuretics.

The common dose for adults is intravenous injection, starting with 1-5 μg/kg per minute according to body weight, and increasing by 1-4 μg/kg per minute within 10 minutes to achieve the maximum therapeutic effect. For chronic refractory heart failure, when starting intravenous drip, gradually increase by 0.5-2 μg/kg per minute according to body weight. For most patients, 1-3 (μg/kg)/minute can take effect. For patients with occlusive vascular lesions, start intravenous drip at 1 (μg/kg)/minute, gradually increase to 5 (μg/kg)/minute, until 20 (μg/kg)/minute, to achieve the most satisfactory effect. For critical cases, first drip at 5 (μg/kg)/minute, then increase by 5-10 (μg/kg)/minute to 20-50 (μg/kg)/minute to achieve a satisfactory effect. Or add 20 mg of this product to 200-300 ml of 5% glucose injection and drip intravenously. Initially, drip at 75-100 μg/min. Later, depending on the blood pressure, the speed and concentration can be increased, but the maximum dose should not exceed 500 μg per minute.

Common symptoms include chest pain, dyspnea, palpitations, arrhythmia (especially with large doses), and general weakness; slow heartbeat, headache, nausea and vomiting are rare. Long-term use of large or small doses in patients with peripheral vascular disease may cause pain or coldness in the hands and feet; prolonged contraction of peripheral blood vessels may lead to local necrosis or gangrene; overdose may cause high blood pressure, in which case the drug should be discontinued and alpha receptor blockers may be given if necessary.

It is contraindicated for those who are allergic to any ingredient of this product.

Precautions for children: This experiment has not been conducted and there is no reliable reference. Precautions for pregnancy and lactation: This experiment has not been conducted and there is no reliable reference.

(1) When used in combination with sodium nitroprusside, isoproterenol, and dobutamine, pay attention to changes in cardiac output, which will be different from the reaction when this product is used alone. (2) When large doses of dopamine are used in combination with alpha-receptor blockers such as phenoxybenzamine, phentolamine, and tolazoline, the vasodilatory effect of the latter can be antagonized by the peripheral vasoconstrictive effect of this product. (3) When used in combination with general anesthetics (especially cyclopropane or halogenated hydrocarbons), the latter can make the myocardium abnormally sensitive to dopamine, causing ventricular arrhythmias. (4) When used in combination with beta-receptor blockers, it can antagonize the effect of dopamine on the beta-1 receptors of the heart. (5) When used in combination with nitrates, it can weaken the anti-anginal effect of nitrates and the pressor effect of dopamine. (6) When used in combination with diuretics, on the one hand, because this product acts on dopamine receptors to dilate renal blood vessels, it increases renal blood flow and can increase the diuretic effect; on the other hand, this product itself has a direct diuretic effect. (7) When used with guanethidine, it can enhance the pressor effect of dopamine, weaken the antihypertensive effect of guanethidine, and lead to hypertension and arrhythmia. (8) When used simultaneously with tricyclic antidepressants, it may increase the cardiovascular effect of dopamine, causing arrhythmia, tachycardia, and hypertension. (9) When used simultaneously with monoamine oxidase inhibitors, it can prolong and enhance the effect of dopamine. It is known that this product is metabolized by monoamine oxidase. For patients who have received monoamine oxidase inhibitors 2-3 weeks before dopamine administration, the initial dose should be reduced to at least 1/10 of the usual dose. (10) Simultaneous intravenous injection with phenytoin sodium can produce hypotension and bradycardia. When using dopamine, if phenytoin sodium must be used for anticonvulsant treatment, the two drugs should be considered for alternating use.

Keep away from light and store in a sealed container.

2ml:20mg

24 months

Yabang Pharmaceutical Co., Ltd.

• Founded in:

  2010-07-22

• Address:

  No. 66, Changhong West Road, Wujin Economic Development Zone, Changzhou

• Tax NO.:

  91320400559287372K

• Registered Funds:

  300 million yuan

• Email:

  Log in to view